BioSpace News Archive

Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced the promotion of Sergi Trilla, MD to become Director of Corporate Strategy & Partnerships.

ZERION Pharma A/S, a Danish pharmaceutical company, elected Dr. Dorte Arnbjerg to join its board of directors at an extraordinary general meeting held on December 14, 2021.

Subsidiary HaluGen Life Sciences has expanded its genetic test panel to include the CYP2D6 gene, a marker indicating the metabolism of LSD, MDMA and ayahuasca.

Experts estimate that 24% of U.S. adults suffer from NAFLD2, and it is estimated there are 34.2 million people with T2D in the United States3 and obesity prevalence has risen to 42.9%4. Metabolic comorbidities with NAFLD include T2D and obesity2, and there are currently no pharmacologic treatments currently approved for either NAFLD or NASH5.

Novaremed AG, a privately held clinical-stage biopharmaceutical company, announces a study with the National Institutes of Health (NIH) under which the NIH will sponsor and conduct a clinical Phase 2b study with Novaremed’s lead non-opioid development compound NRD.E1 in the treatment of painful diabetic peripheral neuropathy (PDPN).

VaxAlta Inc., today announced that it has entered into a licensing and collaboration agreement with Scandinavian Biopharma Holdings AB, a Swedish company specialized in global vaccine development, manufacturing, registration and commercialization of biopharmaceutical products.

Today, the U.S. Food and Drug Administration authorized marketing of the first laser-based device for the removal of Inferior Vena Cava (IVC) filters.

Data from the HIV Prevention Trials Network (HPTN) studies HPTN 083 and HPTN 084 helped provide important information for yesterday’s decision by the U.S. Food and Drug Administration (FDA) to approve ViiV Healthcare’s long-acting cabotegravir (CAB-LA) injections for the prevention of HIV.

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present at the 40th Annual J.P. Morgan Healthcare Conference.

Align Technology, Inc. a leading global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad CAD/CAM software for digital orthodontics and restorative dentistry announced a $1 million donation to the American Association of Orthodontists Foundation, the charitable arm of the American Association of Orthodontists.